By the mechanism of self-adjuvanticity, ATP128 will allow DCs activation, antigenic presentation to tumor specific CD4 and CD8 T cells as observed with KISIMA surrogate treatment in tumor mouse models [1]. This evidence concerns the gene CD4 and neoplasm.